Literature DB >> 30923196

Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection.

Johanna M Sweere1,2, Jonas D Van Belleghem1, Heather Ishak1,3, Michelle S Bach1, Medeea Popescu1,2, Vivekananda Sunkari1, Gernot Kaber1, Robert Manasherob1, Gina A Suh1, Xiou Cao1, Christiaan R de Vries1, Dung N Lam1, Payton L Marshall1,2, Maria Birukova1,2, Ethan Katznelson1, Daniel V Lazzareschi1, Swathi Balaji4, Sundeep G Keswani4, Thomas R Hawn5, Patrick R Secor6, Paul L Bollyky7.   

Abstract

Bacteriophage are abundant at sites of bacterial infection, but their effects on mammalian hosts are unclear. We have identified pathogenic roles for filamentous Pf bacteriophage produced by Pseudomonas aeruginosa (Pa) in suppression of immunity against bacterial infection. Pf promote Pa wound infection in mice and are associated with chronic human Pa wound infections. Murine and human leukocytes endocytose Pf, and internalization of this single-stranded DNA virus results in phage RNA production. This triggers Toll-like receptor 3 (TLR3)- and TIR domain-containing adapter-inducing interferon-β (TRIF)-dependent type I interferon production, inhibition of tumor necrosis factor (TNF), and the suppression of phagocytosis. Conversely, immunization of mice against Pf prevents Pa wound infection. Thus, Pf triggers maladaptive innate viral pattern-recognition responses, which impair bacterial clearance. Vaccination against phage virions represents a potential strategy to prevent bacterial infection.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30923196      PMCID: PMC6656896          DOI: 10.1126/science.aat9691

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  52 in total

1.  Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments.

Authors:  Muriel Gaubin; Cristina Fanutti; Zohar Mishal; Antoine Durrbach; Piergiuseppe De Berardinis; Rossella Sartorius; Giovanna Del Pozzo; John Guardiola; Richard N Perham; Dominique Piatier-Tonneau
Journal:  DNA Cell Biol       Date:  2003-01       Impact factor: 3.311

2.  Refractory venous leg ulcers: a study of risk factors.

Authors:  Guillaume Chaby; Valérie Viseux; Albert Adrien Ramelet; Olivier Ganry; Anne Billet; Catherine Lok
Journal:  Dermatol Surg       Date:  2006-04       Impact factor: 3.398

3.  Monitoring age-related susceptibility of young mice to oral Salmonella enterica serovar Typhimurium infection using an in vivo murine model.

Authors:  Stacy M Burns-Guydish; Isoken N Olomu; Hui Zhao; Ronald J Wong; David K Stevenson; Christopher H Contag
Journal:  Pediatr Res       Date:  2005-03-17       Impact factor: 3.756

4.  TIRAP: an adapter molecule in the Toll signaling pathway.

Authors:  T Horng; G M Barton; R Medzhitov
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

5.  CD14 is required for MyD88-independent LPS signaling.

Authors:  Zhengfan Jiang; Philippe Georgel; Xin Du; Louis Shamel; Sosathya Sovath; Suzanne Mudd; Michael Huber; Christoph Kalis; Simone Keck; Chris Galanos; Marina Freudenberg; Bruce Beutler
Journal:  Nat Immunol       Date:  2005-05-15       Impact factor: 25.606

6.  Targeted immunomodulation of the NF-kappaB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa.

Authors:  Ruxana T Sadikot; Heng Zeng; Myungsoo Joo; M Brett Everhart; Taylor P Sherrill; Bo Li; Dong-sheng Cheng; Fiona E Yull; John W Christman; Timothy S Blackwell
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

7.  Community clinics for leg ulcers and impact on healing.

Authors:  C J Moffatt; P J Franks; M Oldroyd; N Bosanquet; P Brown; R M Greenhalgh; C N McCollum
Journal:  BMJ       Date:  1992-12-05

8.  Double-stranded RNA-mediated TLR3 activation is enhanced by CD14.

Authors:  Hyun-Ku Lee; Stefan Dunzendorfer; Katrin Soldau; Peter S Tobias
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

9.  Bacteriophage and phenotypic variation in Pseudomonas aeruginosa biofilm development.

Authors:  Jeremy S Webb; Mathew Lau; Staffan Kjelleberg
Journal:  J Bacteriol       Date:  2004-12       Impact factor: 3.490

10.  Interferons limit inflammatory responses by induction of tristetraprolin.

Authors:  Ines Sauer; Barbara Schaljo; Claus Vogl; Irene Gattermeier; Thomas Kolbe; Mathias Müller; Perry J Blackshear; Pavel Kovarik
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

View more
  109 in total

1.  Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo.

Authors:  James A Wroe; Christopher T Johnson; Andrés J García
Journal:  J Biomed Mater Res A       Date:  2019-09-05       Impact factor: 4.396

2.  Standardized bacteriophage purification for personalized phage therapy.

Authors:  Tiffany Luong; Ann-Charlott Salabarria; Robert A Edwards; Dwayne R Roach
Journal:  Nat Protoc       Date:  2020-07-24       Impact factor: 13.491

3.  Methods for Extraction and Detection of Pf Bacteriophage DNA from the Sputum of Patients with Cystic Fibrosis.

Authors:  Elizabeth B Burgener; Patrick R Secor; Michael C Tracy; Johanna M Sweere; Elisabeth M Bik; Carlos E Milla; Paul L Bollyky
Journal:  Phage (New Rochelle)       Date:  2020-06-16

4.  Interplay between host-microbe and microbe-microbe interactions in cystic fibrosis.

Authors:  Catherine R Armbruster; Tom Coenye; Lhousseine Touqui; Jennifer M Bomberger
Journal:  J Cyst Fibros       Date:  2019-11-02       Impact factor: 5.482

Review 5.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

Review 6.  Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory.

Authors:  Katherine M Caflisch; Robin Patel
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

Review 7.  Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis.

Authors:  Elio Rossi; Ruggero La Rosa; Jennifer A Bartell; Rasmus L Marvig; Janus A J Haagensen; Lea M Sommer; Søren Molin; Helle Krogh Johansen
Journal:  Nat Rev Microbiol       Date:  2020-11-19       Impact factor: 60.633

8.  A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection.

Authors:  Christiaan R de Vries; Johanna M Sweere; Heather Ishak; Vivekananda Sunkari; Michelle S Bach; Dan Liu; Robert Manasherob; Paul L Bollyky
Journal:  J Vis Exp       Date:  2020-02-20       Impact factor: 1.355

Review 9.  Contact lens-related corneal infection: Intrinsic resistance and its compromise.

Authors:  Suzanne M J Fleiszig; Abby R Kroken; Vincent Nieto; Melinda R Grosser; Stephanie J Wan; Matteo M E Metruccio; David J Evans
Journal:  Prog Retin Eye Res       Date:  2019-11-20       Impact factor: 21.198

10.  The Immune Response to Chronic Pseudomonas aeruginosa Wound Infection in Immunocompetent Mice.

Authors:  Johanna M Sweere; Heather Ishak; Vivekananda Sunkari; Michelle S Bach; Robert Manasherob; Koshika Yadava; Shannon M Ruppert; Chandan K Sen; Swathi Balaji; Sundeep G Keswani; Patrick R Secor; Paul L Bollyky
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-12-18       Impact factor: 4.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.